Searched for
CRDMO INDUSTRY GROWTH
Can domestic formulations shield Indian pharma from US pricing pressure in Q3?Indian drugmakers anticipate a mixed third quarter. Domestic sales and new specialty drugs will drive growth. US generics will see new prod...- Nomura initiates coverage on this recently-listed CRDMO stock, sees 18% upside despite 22% correctionNomura has initiated coverage on Anthem Biosciences with a Buy rating and a ₹740 target, citing attractive valuations, strong CRDMO positio...
- ETMarkets Smart Talk| Aditya Sood sees multi-year upside in financials and domestic manufacturing themesAditya Sood of InCred Asset Management is bullish on India's market, expecting financials and domestic manufacturing to lead wealth creatio...
- India’s generic pharma faces tariff uncertainty but retains edge in US market: JPMorgan analystIndia’s generic pharma faces tariff uncertainty but retains edge in US market: JPMorgan analyst
- Cohance Lifesciences and other pharma stocks jump up to 5% after Jefferies initiates Buy recommendationCohance Lifesciences, Divi’s Laboratories, and SAI Life Sciences rallied after Jefferies initiated coverage with ‘Buy’ ratings, citing stro...
- Anthem Biosciences IPO subscribed 4x on last day; Check GMP, and other key detailsAnthem Biosciences IPO GMP: The IPO attracted strong interest, receiving bids for 17.66 crore shares against 4.4 crore shares on offer. Non...
- Anthem Biosciences IPO subscribed 2x on day 2; Check GMP, and other key detailsAnthem Biosciences' IPO witnessed strong investor interest, being oversubscribed 2.08 times on Day 2, driven by NIIs. Brokerages recommend ...
- Anthem Biosciences' Rs 3,395 crore IPO opens for subscription. Should you bid?Anthem Biosciences launched its IPO on July 14, featuring an offer for sale of Rs 3,395 crore. The Bengaluru-based CRDMO, with a price band...
- India's CRDMO sector can touch USD 25 bn in size by 2035: ReportIndia's CRDMO sector has the potential to reach USD 22-25 billion by 2035, driven by supply chain de-risking, pricing pressures, and demand...
- India becoming an attractive option for global pharmaceutical supply chain: Macquarie ReportIndia's CRDMO industry is projected to grow from USD 7 billion to USD 14 billion by 2028, driven by pharmaceutical outsourcing and regulato...
- Macquarie bullish on Suven Pharma, Divi's Labs, Bluejet and SyngeneMacquarie said that the sector is currently at a turning point, driven by increased pharmaceutical outsourcing due to drug pricing pressure...
- Macquarie initiates coverage on Divi’s Labs, 3 CRDMO firms with up to 40% upside potentialThe global brokerage firm highlights that Indian CDMO companies trade at a 2-year forward EV/EBITDA of 20x, compared to 16x for regional an...
- Buy Piramal Pharma, target price Rs 340: JM FinancialJM Financial recommends buying Piramal Pharma stock. The target price is Rs 340. The current market price is Rs 260.55. India's CRDMO indus...
- Sai Life Science grew fast, but pricing looks expensiveThe issue gives a partial exit to private equity investors TPG Asia and HBM. The promoter share will be diluted from 41.8% to 35.2%. The is...
- India could account for 8-10 pc of work share outsourced to CDMOs by 2033: ReportIndia could take 8-10% of the global outsourcing share for Contract Research Development and Manufacturing Organisations by 2033 due to wor...
- Want to make India a reliable pharmacy of world, says Secretary Department of PharmaceuticalsThe Indian pharmaceutical industry is emerging as a crucial part of the economy, driven by the success of the Make in India initiative and ...
Load More
